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A b s t r a c t  
The objective of present study is to prepare buccoadhesive buccal tablets of Atorvastatin calcium 
(AVC-8mg) using the bioadhesive polymers Carbopol 974P (CP), Guar Gum, and Gum Ghatti as 
matrix forming agent and  Ethyl cellulose (EC-25mg) as impermeable backing layer. The solubility 
studies were conducted along with PEG 4000 in different medias.  Twelve formulations of 
mucoadhesive buccal tablets of AVC were prepared, which contain the polymers in various 
combinations. Tablets were prepared by direct compression method and characterized for swelling 
studies, % matrix erosion, surface pH, bioadhesive properties, in-vitro drug dissolution and in-vitro 
diffusion studies. All the formulations shows the satisfactory results in terms of bioadhesive 
performance. The swelling index was proportional to polymer content. The surface pH of all tablets 
was found to be satisfactory, close to neutral pH; the AVC released and drug diffusion from these 
tablets was depended on the ratio and type of the natural polymers used in the formulation. Tablets 
containing CP (10%) and Guar Gum, HPMCK4M and Gum Ghatti in the ratio of 1:3 (F3,  F7 and F8) 
shows near zero order kinetics release, with non-Fickians diffusion and followed anomalous release. 
The ex vivo permeation concluded that PEG 4000 enhanced the permeability of AVC from the 
tablets. FT-IR studies revealed that there is no interaction between drug and polymer used in the 
study. 
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Introduction 
Among the various routes of drug delivery, oral route is the most 
suitable, convenient and most widely accepted. However, after oral 
drug administration many drugs are subjected to presystemic 
clearance in liver, which often leads to a lack of correlation 
between membrane permeability, absorption and bioavailability 
[1,2]. Here the oral cavity is an attractive site for drug delivery due 
to ease of administration and avoids possible drug degradation in 
the gastrointestinal tract as well as first pass hepatic metabolism. 
This is due to direct access of the drug into the systemic circulation 
through the internal jugular vein bypasses drugs from the hepatic 
first pass metabolism leading to higher bioavailability [3]. 
The buccal mucosa has been investigated for local and systemic 
delivery of therapeutic peptides and other drugs that are subjected 
to first-pass metabolism or are unstable within the rest of the 
gastrointestinal tract.[4] Buccal delivery offers a safer mode of drug 
utilization, since drug absorption can be promptly terminated in 
cases of toxicity by removing the dosage form from the buccal 
cavity.[5] A suitable buccal drug delivery system should possess 
good bioadhesive properties, so that it can be retained in the oral 
cavity for the desired duration. In addition, it should release the 
drug in a unidirectional way toward the mucosa, in a controlled and 
predictable manner, to elicit the required therapeutic response. 
This unidirectional drug release can be achieved using bilayer 
devices.[6] Atorvastatin calcium is HMGCo-A reductase widely 
used in the treatment of hyper lipidemias and cardiovascular 
diseases and it is known to have low oral bioavailability (14%) due 
to an extensive high first-pass effect and its availability in less dose 
size i.e. in few milligrams. Hence, it was considered as suitable 
candidate for administration via buccal route. The aim of the 
present study was to formulate and evaluate buccoadhesive buccal 
tablets of Atorvastatin calcium (AVC) that could be applied to the 
buccal mucosa to release the drug in unidirectional in buccal cavity 
in order to avoid gastric irritation and avoid first pass effect for 
improvement in bioavailability, it also reduce dosing frequency and 
to improve patient compliance. 
Materials and Methods  
Material  
Atorvastatin calcium (AVC) was obtained as a gift sample from 
Aurobindo Pharma, Hyderabad India. Carbopol 974P and ethyl 
cellulose were procured from Correl Pharma Ltd , Sd fine 
chemicals Mumbai, India, respectively. Guar Gum and Gum Ghati 
(Medium Viscosity grade) (H.B Gum, Kalol, India and Raj 
enterprises Mumbai, India, respectively. All other reagents and 
materials were of analytical or Pharmacopoeial grade. 
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Determination of Solubility of Atorvastatin calcium 
An excess of the drug was added to 10mL of the buffer in test 
tubes and the mixture was agitated in a thermo-stable bath at 
37μ1ÀC for 24 hours. Then aliquot was filtered through a whatman 
filter, properly diluted with the same buffer and the absorbance was 
measured at 241nm. The studies were continued to enhance the 
solubility of the drug by using solid dispersions and physical 
mixture.  
Preparation of Physical Mixture and Solid Dispersion 
Physical mixtures of AVC in the mass ratio of 1:3 with PEG 4000 
were prepared in a glass mortar by light trituration for 5 minutes. 
The mixture was passed through a sieve no 60. The prepared 
mixture was then used to perform the study. [7] For the preparation 
of the AVC solid dispersions by dropping method, the composition 
of AVC and PEG 4000 in solid dispersion formulations was in the 
ratio of 1:3 as in accordance to method reported by Lakshmi NV et 
al. [7] The PEG 4000 was melted in a porcelain dish at 580Cμ10C 
and a measured amount of AVC was added and stirred. The 
melted AVC-carrier mixture was pipetted and placed into an 
adjustable heating device to keep the temperature constant. 
Preparation of Atorvastatin calcium Buccoadhesive 
Tablets 
Buccoadhesive tablets were fabricated by the direct compression 
method using the formulations shown in Table 2.  All ingredients of 
the tablets were passed through a sieve no. 40 and were mixed by 
trituration in a glass mortar with pestle to obtain uniform mixing. 
The mixture (100mg) was then compressed using an 8mm 
diameter die on a multi station tablet punching machine. Ethyl 
cellulose (50mg) was added above the core layer and punched 
simultaneously making up to a total weight of 150mg. 
Drug Content Uniformity 
For each formulation, 5 randomly selected tablets were under 
investigation. Each tablet was weighed accurately, powdered and 
transferred into a 50ml volumetric flask containing 30ml of 
methanol and was stirred continuously on a magnetic stirrer. The 
volume was made up to 50ml with methanol and the absorbance 
was measured spectrophotometrically at 241nm. The concentration 
was calculated from calibration curve. 
Bioadhesive strength, surface pH, In vitro Residence 
time and swelling Studies. 
The swelling index of the buccal tablet was evaluated in phosphate 
buffer pH 6.8 The initial weight of the tablet was determined and 
then tablet was placed in 6ml phosphate buffer pH 6.8 in a 
petridish. The tablet was removed at different time intervals (1.0, 
2.0, 3.0, 4.0, 5.0 and 6.0h) blotted with filter paper and reweighed 
(W2). The swelling index is calculated by the formula:  
Swelling index = 100 (W2-W1) / W1. 
                       Where, W1 = Initial weight of the tablet. 
W2 = Final weight of tablet.  
Determination of Surface pH for the prepared Tablets 
The surface pH of the tablets was determined to evaluate the 
possible irritative effects of the formulation on the buccal mucosa. 
The tablets were left to swell for 2 hr in 5ml of phosphate buffer pH 
6.8μ0.05 after 2hrs, the surface pH was measured by placing the 
electrode in contact with the surface of the tablets. 
In-vitro drug release studies 
In vitro drug release was performed by fixing the impermeable 
layer of the tablet with a glass slide using instant adhesive, and 
placed in a beaker containing 900 ml phosphate buffer pH 6.8 as 
dissolution medium. The temperature was maintained at 37μ0.5ĈC 
and the hydrodynamics was maintained by stirring on a magnetic 
stirrer at 50 rpm. 5 ml aliquots were withdrawn at predetermined 
time intervals and replaced with fresh medium. The aliquots were 
analyzed after appropriate dilution by a UV spectrophotometer 
(Elico, Model SL-150, Mumbai, India.) at a wavelength of 241nm. 
The experiments were repeated thrice and the results were taken 
as average of three test readings with standard deviations. The 
amount of AVC present in the samples was calculated with the 
help of appropriate calibration curves constructed from reference 
standards. During the drug release studies, the formulations were 
observed for physical integrity at different time intervals. 
Characterization of release data  
The description of dissolution profiles has been attempted using 
different release models. The data were evaluated according to the 
following equations [8-11]. 
Zero order: Mt = Mo+ Kot 
First order: ln Mt = ln Mo+ K1t 
Higuchi model: Mt = KH “t 
Korsmeyer ăPeppas model: Mt/Mo = Kktn 
Where Mt is the amount of drug dissolved in time t, Mo the initial 
amount of drug,  K1is the first order release constant, K0 the zero 
order release constant, KH the Higuchi rate constant, Kk the release 
constant and n is the diffusional release exponent indicative of the 
operating release mechanism. The correlation coefficient (r2) was 
used as an indicator of the best fitting, for each of the models 
considered. 
Ex vivo Bioadhesion Strength  
A modified balance method was used for determination of the ex 
vivo bioadhesion strength. The balance was modified by 
replacement of one pan with the metal shaft 5gms heavier in 
weight on other pan. A piece of buccal mucosa was fixed on a 
glass vial, which was filled with phosphate buffer pH 6.8, so that it 
just touched the mucosal surface. The vial was fixed to a bottom of 
a glass beaker which is filled with buffer. The tablet was stuck to 
the lower side of a glass slide with cyanoacrylate adhesive. The 
two sides of the balance were made equal before the study, by 
keeping a 5gms of weight on the right hand pan [12-14]. A weight 
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of 5gms was removed from the right hand pan, which lowered the 
slide along with the tablet over the mucosa. The balance was kept 
in this position for 3min contact time. The weight was added slowly 
to the right hand pan until the tablet detached from the mucosal 
surface. This detachment force gave the bioadhesion strength of 
the buccoadhesive tablet in grams (total weight on right hand pan 
minus 5gms).  
In vitro drug permeation Studies 
In vitro drug permeation through sheep buccal mucosa was 
performed using modified Franz diffusion cell at 37μ0.5ĈC. The 
mucosa was mounted between the donor and receptor 
compartments. The prepared Buccoadhesive tablet (F3) was 
placed with the core facing the membrane and a 5gm weight was 
placed over the swollen tablet, the receptor compartment was filled 
with phosphate buffer pH 6.8, and stirred using a magnetic stirrer 
at 50rpm. A 2ml aliquot was withdrawn at predetermined time 
intervals and replaced with fresh medium [15, 16]. The 
absorbanceÊs were measured at 241nm. The results obtained were 
shown in table 3.  
In vitro residence time 
The in vitro residence time for buccal tablet was determined using 
a locally modified USP disintegration apparatus as reported by 
Nakumara et al.[17]. The medium was composed of 800ml of 
phosphate buffer pH 6.8 maintained at 370C. A segment of sheep 
buccal mucosa 3cm length was glued to glass slide. The tablet 
surface was hydrated using phosphate buffer pH 6.8 and then the 
hydrated surface was brought into contact with the mucosal 
membrane, as shown in the below figure. The glass slab was 
vertically fixed to the tablet was completely immersed into the 
buffer solution at the lowest point and was out at the highest point. 
The time necessary for complete erosion or detachment of the 
tablet from the mucosal surface was recorded [18]. 
 
 
Representation of ex vivo residence time 
FT-IR studies 
The compatibility between the drug and polymer was compared by 
FT-IR spectra. The position of peak in FT-IR spectra of pure AVC 
is compared with those in FT-IR spectra of Atorvastatin calcium 
plus excipients. The spectra are shown in Figures 7. 
Stability studies 
Stability studies were conducted for the optimized formulations (F3) 
to assess their stability with respect to their physical appearance, 
drug content and drug release characteristics after storing at 
40ĈC/75% RH for 3 months [22] was seen. 
Results and Discussion 
Mucoadhesive buccal drug delivery system is a promising tool for 
the drugs with low oral bioavailability due to extensive first pass 
effect and also this route provides an easy termination of drug 
effect. Atorvastatin calcium (AVC) is HMG-CoA reductase inhibitor 
with low oral bioavailability due to extensive first pass metabolism. 
In the present work, buccoadhesive tablets of AVC were prepared 
using Carbopol 974P along with guar gum, HPMC K15M, and gum 
ghatti by direct compression method. The amount of drug that 
could be systematically delivered across the buccal mucosa from 
2cm2 system in one day has been estimated to be 10-20mg [9]. 
Hence AVC of dose 8mg was incorporated in the present 
formulations.  
The solubility of the AVC was found be more from 
57.06μ0.67mcg/ml to 81.59μ2.35 and 83.62μ1.76 in the phosphate 
buffer pH 6.8 by using PEG 4000 as physical mixture and solid 
dispersion respectively. Hence an enhancement of solubility with 
PEG 4000 was determined. The results are similar to the Lakshmi 
NV et al. [7]. Hence, this AVC: PEG4000 in the ratio of 1:3 was 
taken in the formulation due to enhancement of solubility. 
Preparation of AVC Buccoadhesive Tablets 
The Buccoadhesive tablets was prepared by direct compression 
method (table 2) using Carbopol 974P(10mg) in fixed concentration 
as a primary polymer along with a secondary polymers like guar 
gum, HPMCK15M and gum ghatti in varying amounts. Ethyl 
cellulose was applied as backing membrane on the matrix core.  All 
the prepared buccal tablets were evaluated for thickness, 
hardness, friability, weight variation, drug content uniformity. The 
results were shown in table 3. The hardness of prepared buccal 
tablets was found to be in the range of 4-5kg/cm2. It was found that 
as the quanitity of polymer in the matrix core was increased, the 
hardness tend to increased. The formulations, F4, F8 and F12 
shows the hardness in the range of 4.54μ0.15, 4.48μ0.35 and 
4.5μ0.19Kg/cm2 respectively. It might be due to absence of the CP 
974P and more amount of  MCC (33%w/w) in the formulations. The 
formulation F7 showed the hardness of 5.06μ0.23Kg/cm2, it might 
be due to the higher amount of HPMC K15M and CP 974P. The 
thickness of the tablets was in range of 1.19μ0.5mm. The drug 
content was from 97.9% to 103.5% suggested uniform mixing of 
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Table  1. Solubility study and drug content for pure drug, physical mixture and solid dispersion 
Drug Mixture 
Solubility (μg/mL)
Drug content (%) 
Water Phosphate buffer 6.8
Pure drug 27.04 μ 0.56 57.06 μ 0.67 94.46μ0.023 
Physical Mixture (1:3) 55.45 μ 1.35 81.59 μ 2.35 98.29μ0.022 
Solid Dispersion (1:3) 57.53 μ 1.46 83.62 μ 1.76 98.48μ0.026 
 





F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
AVC 8 8 8 8 8 8 8 8 8 8 8 8
PEG 4000 24 24 24 24 24 24 24 24 24 24 24 24
Guar gum 15 30 45 30 - - - - - - - -
HPMC K15M - - - - 15 30 45 30 - - - -
Gum ghatti - - - - - - - - 15 30 45 30
CP-974P 10 10 10 - 10 10 10 - 10 10 10 -
Mannitol SD 5 5 5 5 5 5 5 5 5 5 5 5
MCC PH-102 38 23 8 33 38 23 8 33 38 23 8 33
Ethyl cellulose 
(backing layer) 
50 50 50 50 50 50 50 50 50 50 50 50
Total Weight 150 150 150 150 150 150 150 150 150 150 150 150
 
 






Weight Uniformity (mg) 
n=20 




Drug Content (%) 
n=5 
F1 1.09μ 0.04 151μ 0.03 0.47μ0.02 4.65μ0.89 100.1μ 0.02 
F2 1.11μ 0.19 149.1μ 0.1 0.51μ0.05 4.59μ1.22 97.9μ 0.12 
F3 1.15μ 0.03 151.6μ 0.03 0.52μ0.05 4.71μ0.84 103.2μ 0.19 
F4 1.15μ 0.21 147.2μ 0.14 0.52μ0.05 4.54μ0.15 102.1μ 0.14
F5 1.13μ 0.25 148.6μ 0.12 0.53μ0.07 4.54μ0.11 98.3μ 0.07 
F6 1.20μ 0.04 150.1μ 0.34 0.54μ0.06 4.84μ0.35 103.4μ 0.19 
F7 1.19μ 0.05 148.2μ 0.25 0.51μ0.05 5.06μ0.23 102.4μ 0.08 
F8 1.13μ 0.03 147.9μ 0.27 0.52μ0.05 4.48μ0.14 103.5μ 0.05 
F9 1.18μ 0.17 149.6μ 0.16 0.56μ0.08 4.31μ0.19 99.6μ 0.12
F10 1.02μ 0.21 150.3μ 0.34 0.53μ0.05 4.51μ0.21 100.3μ 0.04 
F11 1.14μ 0.26 147.8μ 0.19 0.52μ0.05 4.11μ0.11 98.5μ 0.79 
F12 1.12μ 0.06 149.5μ 0.23 0.56μ0.06 4.51μ0.19 100.1μ 0.29 
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Swelling Index, Surface pH and In vitro Bioadhesion 
Studies 
Bioadhesive polymer swelling is an important aspect in studying 
bioadhesion property. For this study the swelling behavior of the 
prepared buccoadhesive tablets were placed in 5mL phosphate 
buffer solution pH 6.8.The values obtained is shown in Table 4. 
Formulations (F1 to F4) with natural polymer guar gum in 15%w/w, 
30%w/w and 45%w/w in the matrix core, The formulation F3 shows 
highest rate of swelling 295.00μ1.59 with continuous swelling and it 
also maintained the integrity of the tablets till 6hrs, and showed 
higher percentage swelling index, it may be due to the presence 
higher amount of guar gum along with carbopol.  The HPMCK15M 
in 15%w/w, 30%w/w and 45%w/w matrix core formulation (F5 to 
F8) had shown the lowest swelling rate, when compared to both 
guar gum and gum ghatti. The formulation F7 shows 220.05μ2.22 
indicated the lower swelling of the polymer. Among the formulation, 
F9 to F12 the F11 formulation with Gum Ghatti in 45%w/w in the 
matrix core shows 275.00μ1.89 the swelling index, which is an 
intermediary between guar gum and HPMC matrix formulations. 
The percentage swelling index values of the tablets were in the 
order of F1toF4 > F5toF8 > F9toF12. In general, it was observed 
that the percentage swelling index values were found to be 
increased with increasing the concentration of the polymer. The 
swelling of matrix was found to be dependent on the type and 
concentration of polymer matrix core. Further the hydration of the 
polymer results in the relaxation of stretched, entangled or twisted 
molecules, which are able to liberate their adhesive sites giving 
them possibility of creating adhesive bonds. 
The surface pH of the tablets was determined in order to 
investigate the possibility of any side effects, in vivo. As an acidic 
or alkaline pH may cause irritation to the buccal mucosa, it was 
attempted to keep the surface pH as close to as salivary pH. The 
results were shown in table 4. The surface pH for all the prepared 
tablets was  found to be in range of 6.18 to 7.05 which was nearer 
to salivary pH 6.5-7.5. Hence  the prepared buccal tablets can be 
used without the risk of mucosal irritation and discomfort. The 
mucoadhesive properties of the prepared formulations are shown 
in Table 4. The bioadhesion is either attributable to formation of 
physical bonds or hydrogen bonding with the mucus components. 
All the formulations with the Carbopol 974P in the matrix core as a 
primary polymer upto 10%w/w imparting ample bioadhesive 
strength, when compared to formulations (F4, F8 & F12) without 
primary polymer (Carbopol 974P) But, there were effect was 
observed due to the variance in the concentration of secondary 
polymers (guar gum, HPMC and gum ghatti). The bioadhesive 
strength of the tablet was increased gradually with the increase in 
the amount of secondary polymers, and was ranked as HPMC> 
guar gum> gum ghatti.         
The values obtained suggest that the formulation with gum ghatti 
showed lesser adhesion characteristics than the formulation with 
HPMC and Guar gum. The formulation F7 showed the highest 
bioadhesive strength (51.37μ1.55gm) as both the polymers used 
possessed higher bioadhesion strength. The formulations F4 (guar 
gum), F8 (HPMC K15M) & F12 (gum ghatti) had lesser values; it 
might be due to the absence of Carbopol 974P. Thus increased 
sites for bond formation can be attributed to the increase in 
bioadhesion with an increase in concentration [21], and also it was 
found that  an increase in bioadhesion, with the increase in quantity 
of the polymer. All the formulations shown sufficient bioadhesive 
strength and were within the limits. 
 
 
Table 4. Bioadhesive strength, surface pH, In vitro Residence time and swelling index of Different Buccoadhesive Tablets 
Formulation code In vitro Bioadhesive Strength (g) Surface pH In vitro Residence time Swelling IndexmeanμSD 
F1 23.41μ0.75 6.32μ0.03 6 hr 59min 275.00μ0.18
F2 32.19μ0.99 6.91μ0.09 7 hr 59min 289.00μ0.00
F3 41.12μ1.59 6.82μ0.03 7 hr 59min 295.00μ1.59
F4 22.49μ0.57 6.57μ0.06 6 hr 59min 280.00μ1.66
F5 26.99μ0.67 6.03μ0.12 7 hr 59min 177.00μ0.00
F6 37.35μ3.76 6.18μ0.02 >8hrs 213.16μ2.01
F7 51.37μ1.55 6.85μ0.05 > 8hrs 220.05μ2.22
F8 28.73μ0.56 6.22μ0.05 6 hr 49min 180.07μ1.11
F9 21.87μ0.94 6.13μ0.05 6 hr 10min 240.01μ1.11
F10 28.89μ0.54 6.18μ0.08 6 hr 22min 250.20μ1.99
F11 39.52μ0.61 6.36μ0.05 6 hr 35min 275.00μ1.89
F12 19.04μ0.58 7.05μ0.10 6 hr 42min 248.01μ1.11
 
In vitro Drug Release Studies 
The release of AVC from buccoadhesive tablets varied according 
to the type and ratio of the matrix-forming polymers. 
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Effect of Guar Gum along with CP 974P in the Matrix 
Core 
In vitro drug release from (guar gum along with Carbopol934P) in 
the matrix core of buccal tablets, formulation (F3), showed gradual 
decrease in the release rate of AVC, due to the extensive swelling 
of the guar gum with an increase in polymer concentration, which 
forms a thick gel barrier for drug diffusion is shown in figure 1. 
However at higher concentrations, the formulation (F3) with 
45%w/w of guar gum shows a linear release of the AVC, when 
compared to formulations F1 and F2.  Presence of CP 974P in 
formulations F1, F2 and F3 retarded the drug release, but however 
prevented from erosion, and  controlled the release of the drug, 
when compared to  F4 formulation this might be due to the 
absence of CP 974P. The drug release from formulation F1 to F4 




Figure 1. In-vitro Dissolution profile of AVC released from Guar gum based Buccoadhesive tablet (F1-F4) 
 
The correlation coefficient (r2) of the Guar gum matrix tablet (F3) 
for Zero order release kinetics was found to be higher (0.986), 
when compared to that of first order kinetics (0.937) indicating that 
the drug release from the matrix tablets followed Zero order 
kinetics is shown Table 5. From this data, it can be observed that 
formulation F3 (45%w/w guar gum) provides better control over the 
release of AVC than formulations with 15%w/w and 30%w/w of the 
guar gum along with CP 974P  in the matrix core. This might be 
attributed to the cationic interactions between guar gum and CP 
974P in the matrix core. Hence it can be stated that AVC with 
45%w/w of guar gum 10%w/w of CP 974P shows zero order 
release. The Release mechanism, correlation coefficient values (r2) 
for the Higuchi plots (Table 5) ranged from 0.753 to 0.877 for the 
prepared buccoadhesive tablets, indicating that the drug release 
from the tablets occurred by matrix diffusion. The diffusion 
coefficient values for (F3) obtained according to the model 
developed by Korsemeyer et al showed that matrix tablet followed 
case-II transport and a zero order release, as the diffusion 
coefficient ÂnÊ value was found to be greater than 0.89. Hence, the 
results of the study indicated that the release of drug from the 
prepared buccoadhesive tablet followed zero order kinetics via 
diffusion controlled mechanism. 
Effect of HPMC K15M along with CP 974P in the Matrix 
Core 
In vitro drug release studies, HPMC K15M along with 
Carbopol934P in the matrix core of buccal tablets, formulation (F7), 
showed gradual decrease in the release rate of AVC, when 
compared to F5 and F6. It might be due to the formation of intricate 
between HPMC K15M and CP974P. (Figure 2) Formulations F5 
with 15%w/w of HPMC K15M showed rapid release of the AVC, 
when compared to formulations F6 and F7, it is due to lesser 
amount of HPMC K15M. Formulation F8 also shows drug 
sustained release, with a linear fashion. The drug release from 
formulation F5 to F8 were compared and showed in Figure 2. The 
correlation coefficient (r2) of the HPMC K15M buccoadhesive tablet 
(F5) for Zero order release kinetics was found to be higher (0.981), 
when compared to that of first order kinetics (0.934) indicating that 
the drug release from the buccoadhesive tablets followed Zero 
order kinetics. The data is shown in table 5, it may be observed 
that, the Âr2Ê values for prepared buccoadhesive tablets with 15%w 
HPMC in the matrix core are 0.981, 0.934 & 0.872, for tablets with 
30%w/w HPMC in matrix core the Âr2Ê values are 0.969, 0.914 & 
0.842 and 0.979, 0.930 & 0.815 in case of 45% of HPMC in the 
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(45%w/w HPMC) provides better control over the release, over 
other formulations, (30%w/w and 45%w/w of HPMC). This might be 
attributed to the higher concentration of HPMC in the matrix core. 
The diffusion coefficient values obtained according to the model 
developed by Korsemeyer et al showed that matrix tablet followed 
case-II transport and a zero order release, as the diffusion 
coefficient ÂnÊ value was found to be greater than 0.89 (table 5). 
The correlation coefficient values r2 for the Higuchi plots, is ranged 
from 0.815 to 0.872 for the buccoadhesive tablets, indicating that 
the drug release from the tablets occurred by matrix diffusion. 
Hence, the results of the study indicated that the release of drug 
from the prepared matrix tablet followed zero order kinetics via 




Figure  2. In-vitro Dissolution profile of AVC released from HPMC K15M based Buccoadhesive tablet (F5-F8) 
 
In vitro drug release studies of Gum ghatti matrix core 
tablets 
Gum ghatti along with Carbopol934P in the matrix core of buccal 
tablets, formulation (F11), showed gradual decrease in the release 
rate of AVC, formulations showed a gradual decrease in the 
release of drug similar to the release pattern of guar gum. Figure 3, 
however at higher concentrations, the formulation (F11) with 
45%w/w of Gum ghatti shows a linear release of the AVC, when 
compared to formulations F9 and F10.  Presence of CP 974P in 
formulations F9, F10 and F11 retarded the drug release, when 
compared to formulation F12, this might be due to the absence of 
CP 974P. The drug release from formulation F9 to F11 were 
compared and showed in Figure 3.The correlation coefficient (r2) of 
the Gum ghatti matrix tablet (F11) for Zero order release kinetics 
was found to be higher (0.942), when compared to that of first 
order kinetics (0.863) indicating that the drug release from the 
matrix tablets followed Zero order kinetics. From the Table 5 it may 
be observed that, the Âr2Ê values for tablets with 15%w/w gum ghatti 
in the matrix core are 0.970, 0.800&0.823, for tablets with 30%w/w 
gum ghatti in matrix core the Âr2Ê values are 0.960, 0.870&0.772 
and 0.942, 0.863&0.708 in case of 45%w/w of gum ghatti in the 
matrix core for zero order, first order and Higuchi respectively.  
From this data, it can be concluded that formulation F11 (45%w/w 
gum Ghatti along with CP974P) provides better control release of 
AVC when compared to other formulation F9, F10 and F12. The 
diffusion coefficient values obtained according to the model 
developed by Korsemeyer et al showed that matrix tablet followed 
case-II transport and a zero order release, as the diffusion 
coefficient ÂnÊ value was found to be greater than 0.89 (table 5). 
The correlation coefficient values Âr2Ê for the Higuchi plots (table 5) 
ranged from 0.708 to 0.978 for the buccoadhesive tablets, 
indicating that the drug release from the tablets occurred by matrix 
diffusion. Hence, the results of the study indicated that the release 
of drug from the prepared buccoadhesive tablets (F11) followed 
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Figure  3. In-vitro Dissolution profile of AVC released from Gum ghatti based Buccoadhesive tablet (F9-F12) 
 
FT-IR studies 
The drug-polymer interaction was studied using FT-IR 
spectroscopy for selected combination of drug with different 
polymers used. The IR spectrum of AVC gave absorption peak at 
3043cm-1due to hydroxy group (O-H) and in the form of amine with 
absorption peak at 3180cm-1. The IR spectrum of carbopol gives 
absorption peak at 3408cm-1 for its O-H group. The IR spectrum of 
the HPMC K15M exhibited a broad hump around 3411cm-1 to  
 
 
3122cm-1. The IR spectrum of guar gum gives absorption at 
3403.56cm-1 for O-H group of polysaccharide along with carboxylic 
C=O absorption peak at 1654cm-1. The IR spectra of gum ghatti 
gives broad hump at 3411cm-1 for O-H group and absorption peak 
at 1654.05cm-1 for carboxylic C=O. The IR spectrum of pure drug 
and formulation indicates that there is no interaction between the 
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In-vitro Drug permeation study of formulation 
Based on the results, the F3 formulation was selected for in vitro 
drug permeation studies. The oral mucosa of sheep resembles that 
of humans more closely in terms of structure and composition and 
therefore sheep buccal mucosa was selected for drug permeation 
studies. The result of drug permeation from buccal tablets through 
the sheep buccal mucosa is shown in table 4 and figure 5, It reveal 
that AVC was released from the formulation and permeated 
through the sheep buccal membrane and could possibly permeate 
through the human buccal membrane. The drug permeation was 
slow and steady and 79.87μ1.82% of AVC could permeate through 
the buccal membrane within 8hrs.  
Stability Studies 
Stability study was performed on the promising formulation (F3) by 
storing the samples at 400Cμ2ĈC/75%RH for 3 months. The 
samples were tested for any changes in physical appearance , 
drug content and in-vitro drug release studies, The graph was 
shown in figure 6  These results indicate that there were no 
significant changes in Physical appearance, drug content and 
dissolution profile after storage. 
 
 




Figure  6. In vitro dissolution profiles of formulation (F3) before and after storage at 40μ2ĈC /75μ5% RH for 3 months 
  
Conclusion  
The mucoadhesive buccal tablets of Atorvastatin calcium (AVC) 
could be prepared using carbopol 974P as primary polymer along 
with the combination of secondary polymers like HPMC K15M, 
guar gum and gum ghatti by direct compression method. 
Mucoadhesive, Ethyl Cellulose being hydrophobic as backing 
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adhesive capacity of polymers used.  The ex vivo permeation 
concluded that PEG 4000 enhanced the permeability of AVC from 
the tablets. FT-IR studies revealed that there is no interaction 
between drug and polymer. 
Acknowledgements 
The authors are thankful to Aurobindo Pharma, Hyderabad, India, 
and Correl Pharma Ltd , Sd fine chemicals Mumbai, India for 
generously giving the samples of Atorvastatin calcium and 
Carbopol 974P and ethyl cellulose respectively.  
AuthorÊs contribution  
All authors had equally contributed inthe manuscript for literature 
search, study design, in analysis, data collection and interpretation  
analysis, data interpretation, writing etc. If all authors contributed 
equally, please state this 
Conflict of interest  
no conflicts of interest, 
. 
References  
[1]. Santanu RC, Rajesh G, Sourav Saha. 
A Review on Buccal Mucoadhesive 
Drug Delivery Systems. Indo-Global 
Journal of Pharmaceutical Sciences 
2011; 1(3): 223-233.  
[2]. Surapaneni MS, Das SK, Das NG. 
Effect of excipient and processing 
variables on adhesive properties and 
release profile of pentoxifylline from 
mucoadhesive tablets. Drug DevInd 
Pharm 2006; 32(3): 377-87.  
[3]. Gandhi RE, and Robinson JR., 
Bioadhesion in drug delivery, Int. J. 
Pharm. Sci., 1988; 50:145-152.  
[4]. Pranshu T, Satheesh NV. Oral 
mucoadhesive drug delivery systems: 
A review. Int. J. of Bio pharmaceutics 
2011; 2(1): 36-46.  
[5]. Nakhat P, Kondawar A, Babla I, Rathi 
L, Yeole P. Studies on Buccoadhesive 
Tablets of Terbutaline Sulphate. 
Indian J Pharm Sci 2007; 69(4): 505-
10.  
[6]. Yamsani VV, Gannu R, Kolli C, Rao 
ME, Yamsani MR. Development and 
in vitro evaluation of buccoadhesive 
carvedilol tablets. Acta Pharm 2007; 
57(2): 185-97. 
[7]. Lakshmi NV, Kalyan RB, Raj Kumar 
M, Kiran KA, Raju Ch, Sanjeeva KA 
and Venkateshwara Reddy. Improved 
dissolution rate of Atorvastatin 
calcium using solid dispersions with 
PEG-4000, J Chem  Pharm. Res., 
2010; 2(3): 304-311. 
[8]. Higuchi T. Mechanism of sustained-
action medication: theoretical analysis 
of rate of release of solid drug 
dispersed in solid matrices. J Pharm 
Sci 1963; 52:1145ă1149. 
[9]. Korsmeyer RW, Gurny R, Peppas N. 
Mechanisms of solute release from 
porous hydrophilic polymers. Int J 
Pharm 1983; 24: 25ă35. 
[10]. Peppas NA. Analysis of Fickian and 
non-Fickian drug release from 
polymers, Pharm. Acta Helv 1985; 60: 
110ă111. 
[11]. Gohel MC, Panchal MK, Jogani VV. 
Novel mathematical method for 
quantitative expression of deviation 
from the Higuchi model. AAPS Pharm 
Sci Tech 200; 1: 45-50. 
[12]. Ahagon A, Gent AN. Effect of 
interfacial bonding on the strength of 
adhesion. J. Polym. Sci. Polym. Phys 
1975; 13: 1285-1300.  
[13]. Lee VHL, Lee VHK, Robinson JR. 
Controlled drug delivery. 2nd Ed., vol 
29, New York; Marcel Dekker Inc: 
1987, 4.  
[14]. Bomberag LE, Buxton DK, Friden PM. 
Novel periodontal drug delivery 
system for treatment of periodontis. J. 
Control. Rel 2001; 71 (3): 251-259.  
[15]. Jimenez-Castellanous MR, Zia H, 
Rhodes CT. Mucosal drug delivery 
system. Drug Dev. Ind.Pharm 1993; 
19,143-194.  
[16]. Tiwari D, Goldman D, Sause R, 
Madan PL. Evaluation of polyoxy 
ethylene homopolymers for buccal 
bioadhesive drug delivery 
formulations. AAPS Pharm SciTech 
1999; 1:E13. 
[17]. Nakamura F, Otha R, Machida Y, 
Nagai T. In vitro and in vivo nasal 
mucoadhesion of some water soluble 
polymers, Int J Pharm. 1996; 134: 
173-181. 
[18]. Mathias NR, Hussain AM. Non-
invasive systemic drug delivery: 
develop ability considerations for 
alternate routes of administration. J. 
Pharm. Sci 2010; 99: 1-20. 
[19]. Shojaei Amir H. Buccal Mucosa as a 
route for systemic drug delivery. 
Journal of Pharmacy and 
Pharmaceutical Sci. 1998; 1(1): 15-
30.  
[20]. Hoogstraate JAJ, Wertz PW. Drug 
delivery via the buccal mucosa. 
Pharm Sci Techn Today 1998; 1(7): 
309-316. 
[21]. Khairnar GA, Sayyad FJ. 
Development of buccal drug delivery 
system based on mucoadhesive 
polymer. International Journal of 
Pharm Tech Research 2010; 2(1): 
719-735. 
[22]. Mathews BR, Regulatory aspects of 
stability testing in Europe. Drug Dev 
Ind Pharm.  1999; 25: 831ă856. 
  
